BIIB067, which targets a different region of the SOD1 pre-mRNA and is designed for the treatment of ALS patients carrying mutations in the SOD1 gene (Figure 3), was shown to be approximately six times more potent than ASO 333611 in cultured cells and three to four times more potent in inhibiting SOD1 mRNA expression in transgenic rodents. The gene discussed is SOD1; the disease is amyotrophic lateral sclerosis.